319 related articles for article (PubMed ID: 15958765)
1. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.
Ahmadi-Simab K; Lamprecht P; Nölle B; Ai M; Gross WL
Ann Rheum Dis; 2005 Jul; 64(7):1087-8. PubMed ID: 15958765
[No Abstract] [Full Text] [Related]
2. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 treatment in primary Sjögren's syndrome.
Isaksen K; Jonsson R; Omdal R
Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
[TBL] [Abstract][Full Text] [Related]
4. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment.
Meijer JM; Pijpe J; Vissink A; Kallenberg CG; Bootsma H
Ann Rheum Dis; 2009 Feb; 68(2):284-5. PubMed ID: 19139205
[No Abstract] [Full Text] [Related]
5. Successful treatment of Sjogren's syndrome with rituximab.
Touma Z; Sayad J; Arayssi T
Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
[No Abstract] [Full Text] [Related]
6. Successful treatment of refractory neuroSjogren with Rituximab.
Yamout B; El-Hajj T; Barada W; Uthman I
Lupus; 2007; 16(7):521-3. PubMed ID: 17670852
[TBL] [Abstract][Full Text] [Related]
7. [Is rituximab a promising treatment for Sjögren's syndrome?].
Devauchelle-Pensec V; Pers JO; Youinou P; Saraux A
Rev Med Interne; 2008 Dec; 29(12):967-70. PubMed ID: 18403066
[No Abstract] [Full Text] [Related]
8. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
9. [Immunosuppression in Sjogren's syndrome with a pseudo-leukemic lymphocyte reaction].
Orlowski Z; Jedrzejewska T
Pol Tyg Lek; 1970 Oct; 25(42):1588-9. PubMed ID: 5476524
[No Abstract] [Full Text] [Related]
10. Primary Sjogren's syndrome and autoimmune cytopenias: a relation often overlooked.
Khattri S; Barland P
Bull NYU Hosp Jt Dis; 2012; 70(2):130-2. PubMed ID: 22892005
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
Meiners PM; Vissink A; Kallenberg CG; Kroese FG; Bootsma H
Expert Opin Biol Ther; 2011 Oct; 11(10):1381-94. PubMed ID: 21819314
[TBL] [Abstract][Full Text] [Related]
12. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
13. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Saraux A
Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
[TBL] [Abstract][Full Text] [Related]
14. [First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease].
Vasil'ev VI; Logvinenko OA; Kokosadze NV; Gaĭduk IV; Varlamova EIu; Kovrigina AM; Gorodetskiĭ VR; Nasonov EL
Vestn Ross Akad Med Nauk; 2009; (2):3-10. PubMed ID: 19283903
[TBL] [Abstract][Full Text] [Related]
15. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
[TBL] [Abstract][Full Text] [Related]
16. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
Somer BG; Tsai DE; Downs L; Weinstein B; Schuster SJ;
Arthritis Rheum; 2003 Jun; 49(3):394-8. PubMed ID: 12794796
[No Abstract] [Full Text] [Related]
17. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
18. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]